Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...

Gastrointestinal Motility Disorders

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The SEARCH for Evidence: Designing a Game-Based Experiential Learning Intervention for Evidence-Based Medicine.

Medical science educator·2026

Same author

Early and late-onset colorectal cancer in African Americans during COVID-19.

World journal of gastrointestinal oncology·2026

Same author

Role of Prophylactic Endoscopic Gallbladder Stent Placement for Prevention of Acute Cholecystitis in Patients Receiving Stenting for Malignant Biliary Obstruction: A Meta-Analysis.

Digestive diseases and sciences·2025

Same author

Air Cholangiography versus Contrast Cholangiography in Patients with Hilar Biliary Obstruction: A Systematic Review and Meta-Analysis.

GE Portuguese journal of gastroenterology·2025

Same author

Efficacy and safety of polyethylene glycol in combination with linaclotide versus polyethylene glycol alone for colonoscopy: a grade-assessed systematic review and meta-analysis.

Clinical endoscopy·2025

Same author

Assessment of Fecal Occult Blood Testing in Acute Hospital Settings: Perspectives of Internal Medicine Residents in a Multicenter Study.

Cureus·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Tendency of Semaglutide to Induce Gastroparesis: A Case Report.

Ahtshamullah Chaudhry¹, Buluku Gabriel¹, Jawad Noor¹

¹Internal Medicine, St. Dominic Hospital, Jackson, USA.

|February 19, 2024

Summary

Semaglutide, a diabetes drug, can cause gastrointestinal issues. This case report details a patient who developed gastroparesis after starting semaglutide treatment.

Keywords:

gastroparesis nausea and vomiting semaglutide upper endoscopy weight loss and obesity

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Gastrointestinal Motility Monitor GIMM

Gastrointestinal Motility Monitor GIMM

Published on: December 1, 2010

Related Experiment Videos

Last Updated: Jul 2, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Gastrointestinal Motility Monitor GIMM

Gastrointestinal Motility Monitor GIMM

Published on: December 1, 2010

Area of Science:

Endocrinology
Pharmacology

Background:

Semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for type 2 diabetes and increasingly used for weight loss.
Gastrointestinal side effects are known but generally mild.

Observation:

A patient initiated semaglutide therapy.
The patient subsequently developed symptoms suggestive of gastroparesis.

Findings:

The case highlights a potential, albeit uncommon, severe gastrointestinal adverse effect of semaglutide.
Gastroparesis emerged as a complication in this patient receiving semaglutide.

Implications:

Clinicians should be vigilant for severe gastrointestinal symptoms in patients on semaglutide.
Further investigation into the mechanisms underlying semaglutide-induced gastroparesis may be warranted.